Hyloris Outlines Ambitious Growth Strategy During Full-Year Results
Belgian Value-Added Medicines Specialist Wraps Up A Successful Year In Business
Hyloris expects to expand its portfolio to around 30 candidates by 2024, bolstered by €50m in cash and cash equivalents as of the end of 2021.
You may also be interested in...
Hyloris has an eventful year ahead as it plans to conduct numerous trials for products in its ever-expanding pipeline and launch Maxigesic IV in the US.
Hyloris’ partner AFT has signed an exclusive licensing and distribution agreement with Salus Pharmaceuticals covering nine central and eastern European countries. Meanwhile, Hyloris has also struck an in-licensing deal for a new blood phosphorus deficiency treatment.
Hyloris will make payments of up to $6.7m to Vaneltix, alongside a $500,000 loan, to support their collaboration to develop and commercialize Alenura, a first-line drug treatment for acute pain caused by interstitial cystitis that combines lidocaine and heparin.